Cambridge Innovation Capital Research
Investment Thesis
Cambridge Innovation Capital (CIC) is a UK venture investor backing life sciences and deep tech companies, with privileged access to the University of Cambridge's research and IP through a proprietary agreement with the university. The firm describes itself as "driven by people and ideas" and says it was set up with one aim: to increase the successful commercialisation of life sciences and deep tech innovation. It positions itself as a leading Series A investor in the Cambridge ecosystem.
Stage Focus
CIC's early-stage funds focus on Seed and Series A. Its opportunity and growth funds back later-stage companies with scale-up capital. Recent rounds include a $10M seed extension in BeyondMath (Feb 2026), a Series B in Salience Labs ($125M, Oct 2026) and a Series C in Microbiotica (£36M, Oct 2026), the latter two as follow-on participation in larger rounds.
Check Size
CIC does not publish a typical check size. Fund III is a £250M early-stage fund, and CIC has committed at least £100M of it to University of Cambridge spinouts. The website cites over £3.2bn of co-investment capital alongside CIC's own funds, which shows a heavy syndicate practice.
Lead Tendency
Mixed. CIC led the BeyondMath seed extension and is often the first institutional investor in Cambridge spinouts, but it also follows in later rounds led by others, for example Applied Ventures and ICM HPQC Fund in Salience Labs' Series A.
Recent Activity
- October 2026: Salience Labs raised a $125M Series B for photonic networking chips for AI datacentres.
- October 2026: Microbiotica raised a £36M ($48M) Series C to take its pipeline into Phase 2.
- October 2026: Stryker announced a $400M investment in CMR Surgical and a strategic alliance.
- April 2026: Trent AI raised $13M for agentic AI security.
- February 2026: BeyondMath closed an $18.5M seed round after a CIC-led $10M extension.
- February 2025: CIC launched a £100M Opportunity Fund, with a £20M commitment from British Patient Capital.
- August 2025: CIC committed at least £100M of Fund III to Cambridge spinouts and launched an Entrepreneur in Residence programme.
Portfolio Highlights
The website lists over 45 companies and about £0.35bn invested, with around £0.6bn of assets under management. Notable names include CMR Surgical (surgical robotics), Pragmatic Semiconductor, Riverlane (quantum error correction), Salience Labs (photonic computing), Microbiotica (microbiome therapeutics), Bicycle Therapeutics (listed on Nasdaq), Cytora (digital insurance), Gyroscope Therapeutics (acquired by Novartis), Inivata (liquid biopsy) and Audio Analytic (acquired).
Team
- Andrew Williamson: Managing Partner since 2019, 20 years in venture capital including Physic Ventures in San Francisco.
- Michael Anstey: Partner.
- Anne Horgan: Partner.
- Ian Lane: Partner.
- Rob Sprawson: Partner and CFO.
- Edward Inns: Principal.
- Robert Tansley: Venture Partner.
- Sir Nigel Wilson: Chair.
- Andy Neely: Vice Chair.
- Operating Partners: Paul Anson, Ian Jauncey, Dipesh Patel.
- Entrepreneurs in Residence include Damian Crowther, Ferenc Huszar, Mihriban Tuna, Ilana Wisby, Sally Epstein, Laurent Jespers, Rodrigo Santos and Philip Winter.
Decision Process
The firm runs as a partnership with a board and an advisory panel of technical and commercial experts. CIC is authorised and regulated by the UK Financial Conduct Authority. A formal decision timeline is not published.
Founder Preferences
CIC backs scientists and entrepreneurs commercialising research, especially University of Cambridge spinouts and companies in the Cambridge cluster. Its EIR programme and the accelerators it supports (Start Codon, wholly owned, and Deeptech Labs with ARM, the University of Cambridge and Marshalls) pair experienced operators with academic IP to form companies before Series A.
Geographic Focus
Cambridge and the wider UK, with later-round co-investors from the US, Europe and Japan. Companies are mostly Cambridge-based and expand globally.
Gaps
No check size is published. AUM is cited as roughly £0.5bn to £0.6bn across sources, and the USD figure in the payload is an approximation. Portfolio company domains were left null because the portfolio page links to profile pages, not company sites.